Nausea | Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy
Nausea research study
What is the primary objective of this study?
Severe nausea and/or vomiting in patients receiving radiotherapy to the upper abdomen is common despite having received pre-medication with ondansetron, a standard preventive treatment. This study aims to reduce the incidence of significant nausea and/or vomiting with the addition of the NK1-antagonist aprepitant to standard ondansetron treatment. This study will also assess the safety and tolerability of prolonged administration of aprepitant over the 4 to 6 week period of radiation treatment.
Who is eligible to participate?
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:aprepitantaprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
Drug:OndansetronOndansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Active, not recruiting
Start Date: October 2009
Completed Date: August 2016
Phase: Phase 2
Primary Outcome: Complete Response rate (no vomiting and no rescue anti-emetic therapy)
Secondary Outcome: Complete Response rate
Study sponsors, principal investigator, and references
Principal Investigator: Steven Ades, MD MSc
Lead Sponsor: University of Vermont
Collaborator: Mayo Clinic